全部商品分类
rhCEACAM-3/CD66d, CF (50 UG)
下载产品说明书 下载SDS
用小程序，查商品更便捷
收藏
对比
咨询Scientific Data
View LargerWhen Recombinant Human CEACAM-3/CD66d (Catalog # 9868-CM) is coated at 2 µg/mL, Recombinant Human CEACAM-7 (Catalog # 9010-CM) binds with an ED50 of 0.3-3.6 µg/mL.
View Larger2 μg/lane of Recombinant Human CEACAM‑3 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 19-25 kDa.
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9868-CM
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
| Reconstitution | Reconstitute at 500 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: |
|
Recombinant Human CEACAM-3/CD66d His-tag Protein, CF Summary
Product Specifications
Lys35-Gly155, with a C-terminal 6-His tag
Analysis
Background: CEACAM-3/CD66d
Carcinoembryonic Antigen-related Cell Adhesion Molecule 3 (CEACAM‑3), or CD66d, is part of the CEA protein family consisting of CEACAMs and the pregnancy-specific glycoproteins (PSGs). Both CEACAM and PSG molecules have been identified in humans and belong to the much larger glycosylphosphatidylinositol (GPI)‑linked immunoglobulin (Ig) superfamily (1, 2). Mature human CEACAM‑3 is approximately 35 kDa, consisting of an extracellular domain (ECD) containing one IgV‑like domain, a single transmembrane domain and a cytoplasmic tail. The cytoplasmic tail of CEACAM‑3 contains an immunoreceptor tyrosine-based activation motif (ITAM), which recruits kinases to propagate pro-inflammatory signaling cascades (3). CEACAM‑3 appears to be primate specific, with no non-primate orthologs currently identified (4). Originally discovered as a biomarker for colorectal cancer (5), CEACAMs have now been associated with numerous intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (6-8). Unlike other CEA family members, CEACAM‑3 has not been shown to form cell–cell adhesion interactions with other CEACAM family members (9). CEACAM‑3 has been found to be specifically expressed on human neutrophils and other granulocytes and appears to be ann adaptation of the innate immune system to handle specific host pathogens (9). The granulocyte-specific CEACAM epitope is present on at least four CEA family members, CEACAM‑1 -3, -6 and -8, which upon engagement on the neutrophil surface triggers a transient activation signal that requires extracellular calcium and regulates the adhesive activity of the beta2 integrin, CD11/CD18 (10, 11). CEACAM‑3 is critical for opsonin‑independent phagocytosis and bacterial clearance (3). CEACAM‑3 binds to the colony opacity-associated (Opa) outer membrane proteins of bacteria, such as Neisseria gonorrhoeae, and triggers uptake of the pathogen and subsequent elimination (3, 9).
- Beauchemin, N. et al. (1999) Exp. Cell Res. 252:243.
- Zebhauser, R. et al. (2005) Genomics 86:566.
- Schmitter, T. et al. (2004) J. Exp. Med. 199:35.
- Pavlopoulou A. and Scorilas A. 2014 Genome Biol Evol. 6(6):1314.
- Gold P and Freedman SO, (1965) J Exp Med 122:467.
- Obrink, B. (1997) Curr Opin Cell Biol 9:616.
- Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
- Kuespert K et al. (2006) Curr Opin Cell Biol. 18(5):565.
- Pils S. et al. (2008) Int. J. of Med. Micro. 298, 7–8:553.
- Nagel G. et al. (1993) Eur J Biochem 214:27.
- Skubitz KM et al. (1996) J Leukoc Biol 60:106.